Foreign enterprises "slim" movement has begun the local pharmaceutical enterprises to become "take-over man"

In order to save costs, focus on the core areas, improve the efficiency of the use of resources, foreign enterprises through the divestiture of products, transfer of sales rights and other ways to focus on the field of innovative drugs not easy to be copied. Based on the reports disclosed online since 2016, this paper summarizes the information on the introduction of mature products by domestic pharmaceutical companies.
With the expiration of patent protection in China for foreign pharmaceutical companies and the impact of local research and development enterprises, the large number of low-cost generic drugs on the market, sales of foreign pharmaceutical companies in the Chinese market have slowed down, and even shrunk to varying degrees.
the "slimming" movement of foreign companies has begun.
in order to save costs, focus on the core areas, improve the efficiency of the use of resources, foreign enterprises through the divestiture of products, transfer of sales rights and other ways to focus on the field of innovative drugs not easy to be copied. On the other hand, domestic pharmaceutical companies in order to quickly supplement the product line, strengthen the advantages of the field, expand cash flow, enhance the competitiveness of enterprises, have competed to become a "picker."
combined with the online disclosure reports since 2016, this paper summarizes the information on the introduction of mature products by domestic pharmaceutical companies to foreign1 During the cooperation period of Bayer-Drug , Bayer will provide the total package of commercial operations of its five brands of drugs in the Chinese market, such as "White And Black", to SSE Holdings, which will provide Bayer with integrated services including strategy development, marketing promotion, channel management and related work nationwide. The main reason for its cooperation is that Bayer, a large foreign-funded enterprise, is often less flexible in controlling the terminal channel than local enterprises, and Bayer is also looking at the high share of the drug in the grass-roots and drugstore chain markets.
On the other end of the drug, the company set up a national contract sales business headquarters for cooperation, the five varieties will be the sales department business representatives to carry out hospital academic promotion, business channel development and OTC chain terminal coverage, catering to the drug to accelerate the transition to modern pharmaceutical supply chain service enterprises and group strategy. 2 AstraZeneta and AstraZeneta are working together to help them develop their strategic plan in China, the world's second-largest market, to work with local companies to maximize the benefits of pharmaceuticals
. And Kangzhe through cooperation, can fully play the advantages of the first-line sales team, layout channels, effectively improve product coverage and sales.
According to Kangzhe Pharmaceuticals' 2017 semi-annual report, the benefits of academic promotion, enterprises in the solid core market at the same time, strengthen market coverage and penetration, Poyding realized revenue of 643 million yuan, an increase of 134.2% over the same period last year, it can be seen that the advantages of cooperation is gradually visible. 3 Australia's Avita and National Control
Avita is concerned that 3.4 million patients are admitted to hospital each year with burns in China and 1.4 million people suffer from vitiligo skin disease, which is the main application group for Avita's skin care products, Avita entered the Chinese market in 2012, has a better market layout, and this cooperation will be able to better meet the Chinese market demand for Avita renewable medical products. founded in 1995,
Pharmaceutical Holdings Meitai Medical Devices (Shanghai) Co., Ltd., formerly Shanghai Meitai Medical Devices Co., Ltd., is a specialized company focused on hospital modern logistics solutions, operating room and ICU solutions, comprehensive infection control solutions, pharmacy automation solutions and surgical supplies. With more than 3000 hospitals and medical institutions throughout the country to establish a long-term good relations of cooperation, more than 280 employees, this cooperation will enrich the company's sales product line, further bring sales gain. 4 Tyling Pharmaceuticals and Novarma PharmaceuticalsIn May 2016, Tyling Pharmaceuticals announced the acquisition of Novarce Pharmaceuticals' orthopaedic brand," including related intellectual property rights, licenses and other assets, in a deal valued at $145 million. Thailand Pharmaceuticals will have sales networks in major Asia-Pacific regions such as China (including Hong Kong and Taiwan), South Korea, Southeast Asia and India, as well as in Switzerland, Australia, Russia, Brazil and South Africa. For Taling Pharmaceuticals, the acquisition of the Migai brand will enrich its therapeutic product line and strategically enter the orthopaedic field.
's 2017 semi-annual report showed that the secret cover recorded 155 million yuan in the first half of the year, of which 115 million yuan was the brand authorized use fee income, self-employed sales of 39.7 million yuan. 5 French LB and Abao Pharmaceuticals
France LBB and Abao Pharmaceuticals jointly introduced the world's leading people's haemoglobin product VIALEBEX to China, Abao Pharmaceuticals became the product's sole agent in the Chinese market.
In recent years, Yabao Pharmaceuticals to take a "go out, introduce" approach, strengthen international cooperation, from developed countries to introduce advanced management and technology, as well as high-end talent and products, the introduction of VIALEBEX is one of the many international cooperation projects of Abao Pharmaceuticals. In addition, Abao Pharmaceuticals and Lilly in the United States to develop new drugs to treat diabetes; And the British National Institute of Medicine, the Department of Science and Technology to develop new drugs to treat Parkinson's disease; In cooperation with the University of South Australia, a cooperative laboratory has been established to develop new anti-tumor drugs; Working with the Rosen Institute of Health in Canada to develop new drugs to treat sepsis; Working with two Canadian academicians to develop new drugs to treat stroke; Working with Sciecure/salus Pharmaceuticals of the United States to develop 4 slow-release products; In cooperation with Hesse Research and Development Corporation of the United States, we have established a laboratory in Beijing to jointly research innovative drugs and so on.
6 GSK and CadestaIn July 2016, GlaxoSmithKline China announced that it had reached an agreement with Cadesta Pharmaceuticals Holdings to transfer its stake in Nanjing Merry Pharmaceuticals and three urinary products, including Schoenetin Express Tablets, Schoenetin Slow Release Tablets and Nato, with Cadstad taking over the production and sales business.
is understood to be a Chinese-based pharmaceutical company acquired by GSK in 2010 at a cost of US$70 million. Mainly engaged in the diagnosis and treatment of urinary system diseases related products research and production of specialized companies. Through this collaboration GSK will focus its business in China on core areas such as respiratory, hepatitis, vaccines, AIDS, central nervous system and blood clots, and focus on sustained efforts in this area to better provide medical assistance to Chinese patients.
Cadestad Pharmaceutical Holdings Group was founded in 2000, the company's sales scale of 2.53 billion yuan, the average annual growth rate of about 23.8%, in the field of antibiotics, cardiovascular and cerebrovascular market, liver disease, tumor product sales in the industry leader. The successful acquisition will help the Group to improve the layout of the pharmaceutical industry sector, significantly enhance the Group's overall production quality management technology level, and further enrich the Group's product line. Kedesta will take full advantage of Merry's production capabilities, technical strengths and staff skills to continuously develop, providing patients with quality medicines and long-term development and growth opportunities for its employees. 7 Acino and Green leaf pharmaceuticals
At the heart of Greenlee Pharmaceuticals' global strategy is the promotion of the Chinese and international markets through cooperative mergers and acquisitions, research and development innovation, brand marketing, and international quality standards. The acquisition is aimed at Acino, one of Europe's largest manufacturers of independent permeable systems, and the global market for permeable drugs is large and has strong potential growth. The global population aging trend will lead to a sharp increase in the demand for chronic disease management, the persetretic drug business is undoubtedly a huge market. Green leaf pharmaceutical said that the next step will be fully combined with their own experience and advantages in the Chinese market, for the perutertic drug business to open up new market opportunities and development space. 8 AstraZeneta and Sansheng PharmaceuticalsIn October 2016, Sansheng Pharmaceuticals announced that its wholly-owned subsidiary, Hong Kong Sansheng, had entered into an exclusive licensing agreement with AstraZeneta to obtain four products in the latter's diabetes sector for a total licensing price of US$100 million for a period of 20 years. The four products are: Byetta, Bydureon, Bydureondualchamberpen, Bydureonautoinjector. This partnership, Sansheng Group product line in the field of diabetes has been a strong expansion and market penetration, will also integrate AstraZeneta's sales team, to establish a professional team in the field of diabetes, better layout of the field of diabetes. 9 Lilly, SUDA and Eton PharmaceuticalsIn November 2016, pharmaceutical giant Lilly China announced that it had entered into an exclusive agreement with Chinese pharmaceutical company Eton Pharmaceuticals to officially grant the promotion and distribution rights of its anti-biogenic "Hi-Chi-Rao" and "stable and credible" products within the scope of Chinese mainland on January 1, 2017.
this has a certain effect on the content strength of Eden in the field of anti-infection. Prior to this, there was only one anti-infective drug, silhin, on the infection line of Eden. And Lilly's easy-to-master drugs: Hickelau and steady credibility, is Lilly anti-infection product line of the old products, with a high degree of recognition by clinicians.
same month, Eton Pharmaceuticals announced an exclusive commercial licensing agreement for Zolpimist™, a new drug used by SUDA Pharmaceuticals to treat insomnia. The new drug will be the first imported oral spray to be launched in the Chinese market. Through the cooperation, Eden will expand its own product portfolio, the company's business strategy is very consistent.10 Hemney Pharmaceuticals
the domestic pick-up man, the author focused on the more active Tibetan Hamerni pharmaceutical industry. Public information shows that Hemney Pharmaceutical Co., Ltd. started in 2002, is a research and development, production, sales, professional promotion in one integrated pharmaceutical enterprises. Since its establishment, Hamerni Pharmaceuticals, in order to seize the market, in 2013-2017, with a number of enterprises, and constantly enrich their product lines, to ensure the company's market advantage in the field of sales. (New Kangjie)